January 27, 2021 5:32pm

As sector’s last 7 sessions: 5 negative and 2 positive closes expresses the share pricing deflation

News: Applied Genetic Technologies (AGTC) proposes offering of stock and warrants while Pluristem Therapeutics (PSTI) was approved for listing to the Nasdaq Global Market®

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investor profiting!

Are we here to make money or see share pricing erode as earnings LPS (loss-per-share) season is about to begin? Numbers based facts speak better then opinion as I see answers in numbers

To make money in this sector, one has to know when to get out and which individual equity you should stay in!


The Dow closed DOWN -633.87 points (-2.05%); the S&P closed DOWN -98.85 points (-2.57%) while the Nasdaq closed DOWN -355.47 points (-2.61%)

 

Henry’omics:

The sector takes a beat-down … again!

Indexes fell sharply on Wednesday amid disappointing earnings, while concern about heightened speculative trading activity deepened.

The Cboe Volatility Index, known as the VIX or fear gauge, jumped above 28, hitting its highest level in three weeks.

 

Financing news: Applied Genetic Technologies (AGTC) proposes offering of stock and warrants

  • As AGTC dived -0.27 or -5.72% to $4.45,
  • After providing an update on its ongoing clinical trials in patients with achromatopsia (ACHM); believes the additional data reported provides the first reported quantitative evidence of improvements in visual sensitivity, supports the positive patient reported outcomes and provides a path forward to collect additional data to fully realize the potential of this treatment,
  • No numbers or pricing.
  • Stifel, Wells Fargo Securities and MTS Health Partners are acting as joint book-running managers of the offering.

Biostage (BSTG) closed flat at $1.80 with 2,301 shares traded (“pumped” to push share pricing for exercise exercise)

 

Pluristem Therapeutics (PSTI) announced that as of market open on 1/29/21, its common shares have been approved for listing to the Nasdaq Global Market® and will continue trading under the company's current ticker symbol – PSTI.

 

 

Sentiment and COVID-19 infections:

With nearly 80,000 reported deaths through Jan. 26, the first month of 2021 is the deadliest month yet of the Covid-19 pandemic in the United States. The grim January toll surpassed the previous high set in December with five days remaining in the month. <CNBC>

Infection cases <Million>: never to forget …

  • Wednesday 25.45 M cases,
  • Wednesday’s death rate totaled 425,406 <Johns Hopkins University>

 

RegMed Investors’ (RMi) pre-open – none published, spent early morning and late afternoon in testing at local hospital

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Wednesday at the mid-day was negative at 7/25 and 3 flats, closing negative at 4/26, 1 flat and 1 acquired;
  • Tuesday opened negative at 13/21 and 1 flat, stayed negative at the mid-day to 7/26 and 2 flats, closing negative at 3/31 and 1 acquired;
  • Monday opened positive at 22/10 and 3 flats, flipped neutral at 16/16 and 3 flats, strayed negative at the mid-day to 14/20 and 1 flat, flipped again positive at 22/12 and 1 flat closing positive at 21/13 and 1 acquired;

 

Key metrics:

  • Sector volume was LOW with 4 of the 4-upside having higher than the 3-month average volume with the increased volume of 15 of 26-downside having higher than the 3-month average volume;
  • Wednesday’s percentage (%) of the 4-upside were +1.52% (BLUE) to +14.07% (PGEN) while the 26-downside ranges from -2.55% (VSTM) to-14.63% (ALNY);

 

There are clear winners — and losers — heading into the first month of 2021.

Jumping with share pricing momentum:

  • Global Blood Therapeutics (GBT), Precigen (PGEN), bluebird bio (BLUE, MiMedx (MDXG) to name 4 of the 4 inclining of the 35 covered

Hammered in today’s market:

  • Alnylam Pharmaceuticals (ALNY), Intellia Therapeutics (NTLA), ReNeuron (RENE.L), Sage Therapeutics (SAGE), CRISPR Therapeutics (CRSP) to name 5 of the 26 declining of the 35 covered

 

Wednesday’s (4 of 4) incliners:

  • Global Blood Therapeutics (GBT +$3.31);
  • Precigen (PGEN +$1.14);
  • bluebird bio (BLUE +$0.70);
  • MiMedx (MDXG +$0.09);

Tuesday’s (10 of 26) decliners:

  • Alnylam Pharmaceuticals (ALNY -$14.63 after Tuesday’s -$5.67 and Monday’s +$3.31);
  • Intellia Therapeutics (NTLA -$6.14 after Tuesday’s -$7.15 and Monday’s -$2.96);
  • CRISPR Therapeutics (CRSP -$5.58 after Tuesday’s -$11.71 and Monday’s -$7.25);
  • ReNeuron (RENE.L -$4.50 after Tuesday’s -$5.00 and Monday’s -$2.00);
  • Ultragenyx (RARE -$6.79 after Monday’s +$6.29);
  • Ionis Pharmaceuticals (IONS -$3.33);
  • Sage Therapeutics (SAGE -$2.95 after Tuesday’s -$3.50 and Tuesday’s -$6.98 and Monday’s +$1.91);
  • BioLife Solutions (BLFS -$2.52);
  • Cellectis SA (CLLS -$2.32);
  • uniQure NV (QURE -$1.95);

Closing flat 1 Biostage (BSTG) and 1 -Stemline Therapeutics (STML – acquired)

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB closed down -3.02% and XBI closed down -1.35%
  • Tuesday, the IBB closed down -1.74% and XBI closed down -1.76%
  • Monday, the IBB closed up +1.86% and XBI closed up +3%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was up +14.19 points or +61.64% at 37.21
  • Tuesday was down -0.17 points or -0.73% at 23.02
  • Monday was up +1.28 points or +5.84% at 23.19

Upside volume:

  • Wednesday: 4 out of the 4-upside had higher than the 3-month average volume;
  • Tuesday: 9 out of the 31-upside had higher than the 3-month average volume;
  • Monday: 6 out of the 21-upside had higher than the 3-month average volume;

Downside volume:

  • Wednesday: 15 out of the 26-downside had higher than the 3-month average volume;
  • Tuesday: 1 out of the 3-downside had higher than the 3-month average volume;
  • Monday: 7 out of the 13-downside had higher than the 3-month average volume;

 

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

  • Wednesday’s percentage (%) of the 4-upside were +1.52% (BLUE) to +14.07% (PGEN) while the 26-downside ranges from -2.55% (VSTM) to-14.63% (ALNY);
  • Tuesday’s percentage (%) of the 3-upside were +1.37% (BLCM) to +18.42% (BSTG) while the 31-downside ranges from -0.11% (MESO) to-10.01% (NTLA);
  • Monday’s percentage (%) of the 21-upside were +0.10% (CLLS) to +10.82% (ATHX) while the 13-downside ranges from -0.44% (EDIT) to -4.18% (CLBS);

 

January, the 1st month of Q1 …

Wednesday closed negative with 4 advancers, 26 decliners, 1 flat and 1 acquired

Tuesday closed negative with 3 advancers, 31 decliners and 1 acquired

Monday (1/25) closed positive with 21 advancers, 13 decliners and 1 acquired

Friday closed negative with 21 advancers, 13 decliners and 1 acquired

Thursday closed negative with 9 advancers, 25 decliners and 1 acquired

Wednesday closed negative with 18 advancers, 16 decliners and 1 acquired

Tuesday closed positive with 18 advancers, 14 decliners, 2 flats and 1 acquired

Monday (1/18) was a holiday

Friday closed negative with 10 advancers, 24 decliners and 1 acquired

Thursday closed positive with 27 advancers, 7 decliners and 1 acquired

Wednesday closed positive with 10 advancers, 21 decliners and 4 flats

Tuesday closed positive with 21 advancers, 13 decliners and 1 flat

Monday (1/11) closed negative with 13 advancers, 20 decliners and 2 flats

Friday closed negative with 16 advancers, 18 decliners and 1 flat

Thursday closed positive with 31 advancers, 2 decliners and 2 flats

Wednesday closed positive with 22 advancers, 12 decliners and 1 flat

Tuesday closed positive with 19 advancers, 14 decliners and 2 flats

Monday (1/4) closed positive with 26 advancers, 7 decliners and 2 flats

 

The Bottom Line: A deep swing downward … again after an again.

Signs of a bubble continues to concern me, record highs declining quickly. 

There is STILL a short-term tone in the sector – “our’ universe of RegMed, stem, cell and gene therapy equities.

Forewarned … Earnings LPS (los-per-share) season is coming quickly – my advice, trim and skim!!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.